- Report
- August 2025
- 182 Pages
Global
From €3171EUR$3,545USD£2,756GBP
€3523EUR$3,939USD£3,062GBP
- Report
- May 2025
- 200 Pages
Global
From €2227EUR$2,490USD£1,936GBP
- Report
- September 2025
- 250 Pages
Global
From €4016EUR$4,490USD£3,491GBP
- Report
- September 2025
- 250 Pages
Global
From €4016EUR$4,490USD£3,491GBP
- Report
- April 2025
- 175 Pages
Global
From €4016EUR$4,490USD£3,491GBP
- Report
- March 2025
- 200 Pages
Global
From €4016EUR$4,490USD£3,491GBP
- Report
- March 2025
- 175 Pages
Global
From €4016EUR$4,490USD£3,491GBP
- Report
- October 2025
- 144 Pages
Global
From €2682EUR$2,999USD£2,332GBP
- Report
- August 2025
- 200 Pages
United States
From €2227EUR$2,490USD£1,936GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4248EUR$4,750USD£3,693GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4248EUR$4,750USD£3,693GBP
- Report
- February 2024
- 90 Pages
Asia Pacific
From €4248EUR$4,750USD£3,693GBP
- Report
- February 2024
- 80 Pages
Europe
From €4248EUR$4,750USD£3,693GBP
- Report
- February 2024
- 90 Pages
South Korea
From €4248EUR$4,750USD£3,693GBP
- Report
- February 2024
- 70 Pages
Indonesia
From €4248EUR$4,750USD£3,693GBP
- Report
- February 2024
- 70 Pages
Philippines
From €4248EUR$4,750USD£3,693GBP
- Report
- February 2024
- 70 Pages
India
From €4248EUR$4,750USD£3,693GBP
- Report
- February 2024
- 90 Pages
United States
From €4248EUR$4,750USD£3,693GBP
- Report
- February 2024
- 90 Pages
France
From €4248EUR$4,750USD£3,693GBP
- Report
- February 2024
- 70 Pages
United Kingdom
From €4248EUR$4,750USD£3,693GBP

Insulin Glulisine is a fast-acting insulin analog used to treat diabetes mellitus, a metabolic disorder. It is used to control high blood sugar levels in adults and children with type 1 diabetes and adults with type 2 diabetes. It is administered by subcutaneous injection and works by helping the body use glucose for energy. It is also used to treat diabetic ketoacidosis, a serious complication of diabetes.
Insulin Glulisine is a part of the Endocrine and Metabolic Disorders Drugs market, which includes drugs used to treat endocrine and metabolic disorders such as diabetes, thyroid disorders, and obesity. These drugs are used to regulate hormones, control blood sugar levels, and reduce the risk of complications associated with metabolic disorders.
Companies in the Insulin Glulisine market include Eli Lilly, Novo Nordisk, Sanofi, and Biocon. Show Less Read more